AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will present at the 31 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 8:30 am Pacific Time. The presentation will include a company overview and business update.
A live webcast of the presentation will be accessible through the Investors section of the company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until February 9, 2013.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that manufactures and markets Feraheme® (ferumoxytol) Injection for Intravenous (IV) use in the United States. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company’s commercial footprint and focus on hematology and oncology centers and hospital infusion centers. For additional company information, please visit
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts